How Vertex's New Deal Could Transform Drug Delivery

Halozyme Therapeutics and Vertex Pharmaceuticals have entered a partnership to license Halozyme's Hypercon technology, involving a $15 million upfront payment and potential future milestones. Vertex will use the technology for up to three drug targets. Hypercon aims to reduce injection volumes, facilitating at-home drug administration. Halozyme will receive royalties on sales of products developed with Hypercon. This collaboration enhances Halozyme's drug delivery portfolio, which includes Enhanze technology, already licensed to major pharmaceutical companies.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.